IRD vs TTAN
IRD: Opus Genetics is a clinical-stage gene therapy company developing a portfolio of durable, one-time treatments for rare inherited retinal diseases. TTAN: ServiceTitan is an agentic operating system designed to automate, manage, and scale the workflows of professional contracting and trade businesses.
Side-by-side fundamentals
| Metric | IRD | TTAN | Edge |
|---|---|---|---|
| Price as of 2026-09-09 close | $5.73 | $57.12 | |
| Market cap as of 2026-09-02 | $477M | $8.9B | |
| PEG as of 2026-09-02 | n/a | 1.89 | |
| Net margin | -349.3% | -16.6% | TTAN higher |
| Gross margin FY2026, SEC XBRL | n/a | +70.1% | |
| Operating margin | -271.9% | -17.6% | TTAN higher |
| ROE | -323.1% | -10.5% | TTAN higher |
| ROA | -98.7% | -9.2% | TTAN higher |
| Debt / equity as of 2026-09-02 | 0.07 | 0.00 | TTAN lower |
| Revenue growth (YoY) as of 2026-09-02 | -12.2% | +24.1% | TTAN higher |
| Revenue CAGR (3y) SEC XBRL | -29.1% | +27.1% | TTAN higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 0.83 | 0.90 | |
| 1-year return as of 2026-09-09 close | +321.3% | -52.2% | IRD higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-09-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.